摘要
As an important enzyme for gluconeogenesis, mitochondrial phosphoenolpyruvate carboxykinase(PCK2) has further complex functions beyond regulation of glucose metabolism. Here, we report that conditional knockout of Pck2 in osteoblasts results in a pathological phenotype manifested as craniofacial malformation, long bone loss, and marrow adipocyte accumulation. Ablation of Pck2 alters the metabolic pathways of developing bone, particularly fatty acid metabolism. However, metformin treatment can mitigate skeletal dysplasia of embryonic and postnatal heterozygous knockout mice, at least partly via the AMPK signaling pathway.Collectively, these data illustrate that PCK2 is pivotal for bone development and metabolic homeostasis, and suggest that regulation of metformin-mediated signaling could provide a novel and practical strategy for treating metabolic skeletal dysfunction.
基金
supported by the National Natural Science Foundation of China(81870742,81930026,81970911)
China Postdoctoral Science Foundation(2020TQ0020,2021M700280)
Natural Science Foundation of Beijing(7202233)
Research Foundation of Peking University School and Hospital of Stomatology(PKUSS20210102)。
